AIDS vaccines
Researchers from Amsterdam University Medical Center have published a study in PLOS Pathogens detailing the development of a vaccine that induces both neutralizing antibodies and antibody-mediated effector functions against HIV-1. This breakthrough could potentially curb the ongoing global HIV-1 epidemic. The vaccine, ConM SOSIP.v7, was tested in preclinical and
AIDS vaccines
Researchers from Amsterdam University Medical Center have published a study in PLOS Pathogens detailing the development of a vaccine that induces both neutralizing antibodies and antibody-mediated effector functions against HIV-1. This breakthrough could potentially curb the ongoing global HIV-1 epidemic. The vaccine, ConM SOSIP.v7, was tested in preclinical and
AIDS vaccines
Despite promising results in preclinical settings, major efficacy trials of HIV vaccines have failed to meet endpoint efficacy criteria, raising questions about how to optimize modeling of the clinical reality facing HIV-1 vaccine developers. Researchers have highlighted the need to address gaps in translation between preclinical and clinical settings in
HIV
A recent study on the Immune System Diseases and Conditions - HIV/AIDS has shed light on how sex, race, and geographic location may influence the effectiveness of HIV vaccines. The research, conducted by LMU University Hospital, involved a randomized, double-blinded, placebo-controlled phase 2 trial that enrolled 480 Black and
AIDS vaccines
Researchers at Quaid-i-Azam University have made significant progress in the development of an effective HIV vaccine. The study aimed to characterize the Pol, Vpr, and Nef genes, and design a multi-epitope vaccine using computational tools. The research involved extracting RNA from HIV-positive samples, converting it into complementary DNA, and processing
AIDS vaccines
Researchers at Quaid-i-Azam University have made significant progress in the development of an effective HIV vaccine. The study aimed to characterize the Pol, Vpr, and Nef genes, and design a multi-epitope vaccine using computational tools. The research involved extracting RNA from HIV-positive samples, converting it into complementary DNA, and processing
AIDS vaccines
A recent study on the Immune System Diseases and Conditions - HIV/AIDS has shed light on how sex, race, and geographic location may influence the effectiveness of HIV vaccines. The research, conducted by LMU University Hospital, involved a randomized, double-blinded, placebo-controlled phase 2 trial that enrolled 480 Black and
AIDS (Disease)
Research has shown that people living with HIV/AIDS (PWHA) are at a higher risk of developing non-cervical cancers, particularly anal, vaginal, vulvar, penile, and oropharyngeal cancers. A study conducted by Imperial College London found that PWHA are 30.32 times more likely to develop anal cancer, 15.78 times
AIDS vaccines
Rockefeller University has made a groundbreaking discovery in the fight against HIV with the publication of a patented broadly neutralizing antibody that has the potential to prevent HIV infection. The patent, filed on March 6, 2024, and published online on September 30, 2025, describes a non-naturally occurring anti-HIV gp120 antibody
AIDS vaccines
The World Health Organisation (WHO) has made a significant endorsement for the use of injectable lenacapavir, administered twice yearly, to provide near-total protection against HIV infection. This breakthrough was announced during the 13th International AIDS Society (IAS 2025) Conference on HIV Science in Kigali, Rwanda, where the new WHO guidelines
AIDS vaccines
Researchers from Universidad Catolica de Murcia have made significant progress in developing vaccines against monkeypox, a zoonotic illness caused by the monkeypox virus (MPXV). According to the World Health Organization, the recent outbreak has prompted a global health emergency declaration, highlighting the critical need for effective vaccine solutions. The study
